Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).
about
Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumabFingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidenceWhat do we know about brain contrast enhancement patterns in neuromyelitis optica?Ultrahigh field MRI in clinical neuroimmunology: a potential contribution to improved diagnostics and personalised disease managementHypoxemia, Sleep Disturbances, and Depression Correlated with Fatigue in Neuromyelitis Optica Spectrum Disorder.Restoring immune tolerance in neuromyelitis optica: Part IITreatment of neuromyelitis optica: state-of-the-art and emerging therapiesTreatment of primary Sjögren syndrome.[Tryptophan immunoadsorption for multiple sclerosis and neuromyelitis optica: therapy option for acute relapses during pregnancy and breastfeeding].MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcomeNeuromyelitis optica: clinical features, immunopathogenesis and treatment.[Contribution of spinal cord biopsy to the differential diagnosis of longitudinal extensive transverse myelitis].Longitudinally extensive transverse myelitis in neuromyelitis optica: a prospective study of 13 Caucasian patients and literature review.The Diagnosis and Treatment of Optic NeuritisFatigue in patients with neuromyelitis optica spectrum disorder and its impact on quality of life.Systemic Lupus Erythematosus (SLE) Complicated by Neuromyelitis Optica (NMO - Devic's Disease): Clinic-Pathological Report and Review of the Literature.Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate.Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositivepatients in a Chinese population.The Urine Proteome Profile Is Different in Neuromyelitis Optica Compared to Multiple Sclerosis: A Clinical Proteome StudyNext-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis.The intrathecal, polyspecific antiviral immune response in neurosarcoidosis, acute disseminated encephalomyelitis and autoimmune encephalitis compared to multiple sclerosis in a tertiary hospital cohort.The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica.A Case Study of Intractable Vomiting with Final Diagnosis of Neuromyelitis OpticaA diagnostic challenge in a young woman with intractable hiccups and vomiting: a case of neuromyelitis opticaEfficacy and safety of rituximab in neuromyelitis optica: Review of evidence.Present and Future Therapies in Neuromyelitis Optica Spectrum DisordersImmunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorderSerum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis.A Urinary Metabolic Signature for Multiple Sclerosis and Neuromyelitis OpticaHigh avidity chimeric monoclonal antibodies against the extracellular domains of human aquaporin-4 competing with the neuromyelitis optica autoantibody, NMO-IgG.Placebo-controlled study in neuromyelitis optica-Ethical and design considerationsImmunoadsorption in patients with neuromyelitis optica spectrum disorder.Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder.MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients.MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.Development of a patient-centred conceptual framework of health-related quality of life in neuromyelitis optica: a qualitative study.Recent advances in the neuroimmunology of cell-surface CNS autoantibody syndromes, Alzheimer's disease, traumatic brain injury and schizophrenia.
P2860
Q21146701-EBDDFB57-5060-4951-A9B8-A4AE85C58176Q26752466-E86B1DA0-5CE7-495E-8587-940DF206E5D5Q26776278-E91242F9-E8A3-4821-AD7E-6FAF57D707B4Q26796643-1B3D118C-CF24-480F-AA3C-4D38239D2201Q27313852-1C8FA8C1-C9A0-4454-8094-E83339B50619Q28070136-BB677AA9-CBC0-4A57-B1D6-DBE5916CC3FFQ28245749-52C30199-076A-4E72-96F3-77B36D011D20Q30249011-3C3E8A41-8CB7-4D8F-B48F-6A6762EBE95DQ30316840-7B2D18D1-B587-4AC1-9699-86217041D0ACQ30371412-A46D1694-307D-45B2-BC43-FB06BA9902EDQ30785267-719AEEA4-8227-4B24-917F-3EA94BAC1C93Q30844319-4F34045E-DD7C-46B2-BFB6-9AA9A97C1F9CQ30945169-9D4459AA-8BF3-48F8-9B57-896FEDDFBF75Q30995944-46F22E60-95DD-46E7-BEF6-166678312772Q33719007-F918D972-2BA7-44AC-B8CD-00CE424D7E45Q33734731-3F77181E-2C9F-45AB-9C8D-53E79F72A7D2Q34026880-F6F2BE8C-1C79-4B7B-9612-F163C659A424Q34545836-2C56FB71-EC7D-4133-8176-D92F2FF5C357Q35228937-FB65E4AA-81DF-4DCC-9976-B10F7F902321Q35763927-3B244541-BCD3-4EDD-9A4B-2C975AFD7101Q35804573-EC400769-8043-448D-BBC3-4A0E2350CE42Q35828632-A1E5B76C-BCFD-4800-B41E-D4AE282F3013Q35864847-5EE131D1-34C0-44F2-90C4-D0C204B47BA7Q36171516-1D5A9F23-D0C4-4C19-B511-895E9357FD8BQ36174210-F0348255-C1C0-45EF-BBC0-8802567A73D7Q36181695-D476EF6D-E1CA-4A44-9579-CC0CBE48F097Q36359371-E924C817-7B82-4801-AD13-5EADB466E5AEQ36484394-EECCD448-631B-48A4-9AD4-452BB92E443BQ36484399-BA1A54D4-24D4-4955-B107-724F708E2DB2Q36490876-848155F7-5DD9-4AC6-A403-15CC0AE24187Q36562604-1A4AB623-87BB-48F7-B826-D76A5602B0A9Q36635131-6779DEF0-2AE1-4FC9-8430-24635B4E578FQ36744223-55B46037-0DFB-4E86-A24C-50C59FEA2600Q36996492-55AC2B19-26E6-4F02-8E53-63600ED807CEQ37027700-126EEEE9-E690-476A-B960-3F96728214EFQ37365089-4A4259CA-E317-40C2-9776-FCA5D6D4491AQ37383474-06FE47A6-B3FA-48A8-A46F-96D89EA26C01Q37383555-97C80C3E-70BE-4CE3-9954-B87856B2C057Q37567603-F46FADE3-60F3-474F-AEE0-0E90A5F41EDCQ38245624-3037C3B0-1D71-4EF2-A8AB-48AD90278507
P2860
Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Update on the diagnosis and tr ...... is Optica Study Group (NEMOS).
@ast
Update on the diagnosis and tr ...... is Optica Study Group (NEMOS).
@en
type
label
Update on the diagnosis and tr ...... is Optica Study Group (NEMOS).
@ast
Update on the diagnosis and tr ...... is Optica Study Group (NEMOS).
@en
prefLabel
Update on the diagnosis and tr ...... is Optica Study Group (NEMOS).
@ast
Update on the diagnosis and tr ...... is Optica Study Group (NEMOS).
@en
P2093
P2860
P1433
P1476
Update on the diagnosis and tr ...... is Optica Study Group (NEMOS).
@en
P2093
Achim Berthele
Brigitte Wildemann
Corinna Trebst
Ingo Kleiter
Nadja Borisow
Neuromyelitis Optica Study Group (NEMOS)
Orhan Aktas
Sven Jarius
Sven Schippling
P2860
P2888
P356
10.1007/S00415-013-7169-7
P577
2013-11-23T00:00:00Z
2014-01-01T00:00:00Z